Late filing
elevated
Filing comparison
Akari Therapeutics Plc filed its quarterly report late and said it expects a significant change in results
expects significant change in results 3 days past the statutory due date.
The Quarterly report on Form 10-Q for the period ended March 31, 2026 (“Quarterly Report”) of Akari Therapeutics, Plc (the “Company”) could not be filed on schedule due to management and counsel devoting substantial time and resources to matters relating to the Company’s previously announced upcoming public offering and the disclosures related thereto.
Evidence
- Anticipates significant change
- Yes
- Days past due date
- 3
- Routine
- No
- Severity
- elevated
- Source
- Form 12b-25 (notification of late filing)
- Stated reason
- The Quarterly report on Form 10-Q for the period ended March 31, 2026 (“Quarterly Report”) of Akari Therapeutics, Plc (the “Company”) could not be filed on schedule due to management and counsel devoting substantial time and resources to matters relating to the Company’s previously announced upcoming public offering and the disclosures related thereto.
- Why
- The company told the SEC it could not file a periodic report on time, using Form 12b-25.